Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Nvo save search
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
haemophilia phase 3
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.4 -0.42% -0.42% 11K
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial
Published: 2021-06-26 (Crawled : 04:20) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood injection phase 3 trial
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Published: 2021-06-26 (Crawled : 04:20) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood phase 3 trial
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Published: 2021-04-21 (Crawled : 14:00) - globenewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.4%
H: 1.1%
C: 0.9%
obesity ev phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.